



# HEMATOPOIETIC & LYMPHATIC SYSTEM

SUBJECT : Pathology

LEC NO. : 7

DONE BY : Ruba Almshaqba

وَقُلْ رَبِّ زِدْنِي عِلْمًا



2 types of classification

1. WHO

## ❖ Classification 2. FAB

➤ AMLs are diverse in terms of genetics, cellular lineage, and degree of maturation.

➤ **The WHO classification relies on these features to divide AML into four categories:**

(1) AMLs associated with specific genetic aberrations *Ex: translocations*

(2) AMLs with *abnormal morphological changes in cells* dysplasia, many of which arise from *myelodysplastic syndromes* MDSS

(3) AMLs occurring after chemotherapy

(4) AMLs lacking any of the foregoing features (subclassified based on the predominant line of differentiation that the tumor exhibits) **NOS**

## WHO Classification of AML 2016 Revision: AML and Related Neoplasms

### AML with recurrent genetic abnormalities

- AML with t(8;21)(q22;q22.1);*RUNX1-RUNX1T1*
- AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);*CBFB-MYH11*
- APL with *PML-RARA*
- AML with t(9;11)(p21.3;q23.3);*MLLT3-KMT2A*
- AML with t(6;9)(p23;q34.1);*DEK-NUP214*
- AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); *GATA2, MECOM*
- AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);*RBM15-MKL1*
- Provisional entity: *AML with BCR-ABL1*
- AML with mutated *NPM1*
- AML with biallelic mutations of *CEBPA*
- Provisional entity: *AML with mutated RUNX1*

### AMLs with myelodysplasia-related changes

### Therapy-related myeloid neoplasms

### AML NOS

- AML with minimal differentiation
- AML without maturation
- AML with maturation
- Acute myelomonocytic leukemia
- Acute monoblastic/monocytic leukemia
- Pure erythroid leukemia
- Acute megakaryoblastic leukemia
- Acute basophilic leukemia
- Acute panmyelosis with myelofibrosis

Arber DA, et al. *Blood*. 2016;127:2391-2405.

# FAB (French American British) classification of AML

الدكتورة ما بدها الأرقام بس مطالبين من  
M0 to M7 التصنيف فقط

## AML-M0 (minimally differentiated)

→ >20% blasts  
<3% blasts are MPO +

Myeloid antigens +

No Auer rods

## AML-M1 (without maturation)

With differentiation

Most of the cells are myeloblast

→ >20% blasts

>3% blasts are MPO+

<10% promyelocytes or mature cells

## AML-M2 (with maturation)

نسبة اكبر من الخلايا صارت تشبهه

promyelocyte

→ >20% blasts

>3% blasts are MPO+

>10% promyelocytes or mature cells

<20% monoblasts and promonocytes

### AML-M3 (acute promyelocytic leukemia)

نسبة ال promyelocyte أكبر من M2

① تتميز بوجود عدد من ال Auer rods

>20% blasts and promyelocytes

Intense MPO reactivity

② Associated with t(15,17)

③ High incidence of DIC (Disseminated Intravascular Coagulation)

### AML-M4 (acute myelomonocytic leukemia)

Mixture of cells (myeloblasts, monoblasts, promonocytes)

>20% myeloblasts, monoblasts, promonocytes

Monocytic cells range from 20%-80%

Cells stain positive with lysosomal non-specific esterase.

### AML-M5 (acute monoblastic and monocytic leukemia)

معظم الخلايا تشبه ال monoblasts + monocytes

>20% monoblasts, promonocytes and myeloblasts

>80% monoblastic cells (5A) or monocytic (5B)

No Auer rods

MPO -

## AML-M6a (Erythroleukemia)

Mix with erythroid precursors

بس نسبتهم اقل

>50% are erythroid precursors

>20% myeloblasts among non-erythroid cells

## AML-M6b (pure erythroid)

زادت نسبة ال erythroid precursor

>80% of marrow cells are immature erythroid cells

No significant myeloblastic component

## AML-M7 (megakaryocytic)

>20% blasts

>50% megakaryocytic cells

# AML Course & Prognosis

ال prognosis لل ALL افضل

- Rapidly fatal if untreated.
- With chemotherapy, 70% remission rate and 15-20% 5-year survival.

## -Prognostic Factors

Patient age

WBC count at presentation

De novo vs. Secondary leukemia

Cytogenetic abnormalities

### ❖ Good prognosis

t(15;17)

t(8,21)

inv(16)

Some genetic abnormalities

### ❖ Poor prognosis

Age >60 y

Prior MDS (dysplasia)

Therapy-related AML

Leukocytosis >100,000/ $\mu$ L

Early relapse بعد علاج ال tumour رجع كمان مرة

del 5 or 7

t(9;22)

Important



# The major differences between AML and ALL



| Feature                | AML  | ALL  |
|------------------------|--|--|
| <b>Age</b>             | Common in adults<br>Rare in children   | Common in children<br>Rare in adults   |
| <b>Blood</b>           | Myeloblasts  | Lymphoblasts   |
| <b>Morphology</b>      | <ul style="list-style-type: none"> <li>Medium to large blasts</li> <li>More cytoplasm</li> <li>Cytoplasmic granules</li> <li>Auer rods</li> <li>Fine chromatin</li> <li>Distinct nucleoli → Large</li> </ul> | <ul style="list-style-type: none"> <li>Small to medium blasts</li> <li>Little cytoplasm</li> <li>No granules (90%)</li> <li>No Auer rods</li> <li>Fine chromatin</li> <li>Indistinct nucleoli → Small</li> </ul> |
| <b>Myeloperoxidase</b> | Positive   | Negative   |
| <b>TdT</b>             | Negative   | Positive   |
| <b>CD Markers</b>      | CD13,CD14<br>CD15,CD33,CD64  | CD10,CD19,CD20<br>CD21,CD23,CD79a  |



Morphologic comparison of lymphoblasts and myeloblasts.


**A. ALL:** Lymphoblasts have fewer nucleoli than do myeloblasts, and the nuclear chromatin is more condensed. Cytoplasmic granules are absent.

**B. AML:** Myeloblasts have delicate nuclear chromatin, prominent nucleoli, and fine azurophilic granules in the cytoplasm





# Neoplastic Proliferations Of White Cells



# Myeloproliferative Neoplasms (MPN)

## WHAT ARE MYELOPROLIFERATIVE NEOPLASMS (MPN)?

يمكن تأثر على اي نوع من الخلايا



- ❖ A family of **acquired malignant clonal disorders** of **pluripotent stem cells** with resulting **abnormalities in one or more cell lines.**
- ❖ At least initially, the clonal stem cells **retain their capacity for terminal differentiation.**
- ❖ The hallmark of MPN is the presence of mutated, **constitutently active tyrosine kinases** or other acquired aberrations that lead to **growth factor independence.**

ال acute leukaemia بختلف بانه عنده مشكلة في ال  
immature cells differentiation فيتكون من  
mature looking MPN ال يكون مكون من  
بس هي abnormal functionally

○ Four major diagnostic entities are recognized

---

1. Chronic myeloid leukemia (CML)

2. Polycythemia vera

3. Essential thrombocythemia

4. Primary myelofibrosis

## ○ General characteristics

---

○ **Hyper**cellular marrow with **matur**ation

○ **Effective** hematopoiesis peripheral blood ال bone marrow رح تطلع على ال لانه الخلايا الموجودة في ال

○ Elevated peripheral blood levels of one or more cell lines:

○ granulocytic (CML)

اي نوع من الخلايا ممكن يتأثر و حسب نوع

○ erythroid (polycythemia vera)

Myeloproliferative Neoplasms رح تكون الزيادة

○ platelets (essential thrombocythemia)

○ Hepatosplenomegaly

○ These disorders have many overlapping features.

# 1. Chronic Myeloid Leukemia (CML)

- A disorder characterized by massive **overproduction** of normal-appearing but somewhat **defective granulocytes**.
- **Adults** between 25 and 60 years (peak in 4<sup>th</sup>-5<sup>th</sup> decades).

## □ Differential diagnosis

- ①
- **Leukemoid reaction** (a dramatic elevation of the granulocyte count in response to infection, and chronic inflammation),,,,,, **Distinction can be achieved by testing for the presence of the BCR-ABL fusion gene.**

في هاي الحالات بنروح لل genetic testing مثل :

EX


- ②
- Other **MPN**

## □ Pathogenesis:

- In ~ 95% of cases, there is a **t(9;22) (Philadelphia chromosome)** that *results in a chimeric BCR-ABL gene* which encodes a fusion protein with **tyrosine kinase activity**. ال hybrid gene ال proliferation ال قدرة الخلايا على ال

-The mutation is a stem cell mutation (found in granulocytes, erythroid, megakaryocytes, B and T precursors); however, **the effect is limited to granulocyte and megakaryocyte**.


The BCR-ABL fusion gene is present in hematopoietic stem cells, as well as their progeny, including granulocytes, erythroid cells, megakaryocytes, and B and T cell precursors. However, the oncogenic effect of the BCR-ABL fusion protein is primarily limited to the granulocyte and megakaryocyte lineages





## ❑ Clinical Features

- Early: patients appear normal
- The onset is insidious.
  - The initial symptoms usually are nonspecific (e.g., anemia with fatigue, weakness, anorexia, weight loss)
  - Bleeding tendencies.
  - Infections.
- Dragging sensation in the abdomen caused by splenomegaly.
- Median survival of **3** years, even without treatment



## ❑ Laboratory Findings <sup>من</sup> mature megakaryocytes and granulocytes ال مهم الزيادة بتكون في ال

BP peripheral blood على bone marrow رح تطلع في ال <sup>لانه</sup> حكيئا الخلايا يلي تصنعت في ال

- The leukocyte count is elevated, often exceeding 100,000 cells/ $\mu$ L. <sup>↑ granulocytes</sup>
- The circulating cells are predominantly neutrophils, metamyelocytes, and myelocytes, but basophils and eosinophils are also prominent
- High platelet counts (early), thrombocytopenia (late) <sup>↑ megakaryocytes</sup>
- Mild to moderate anemia
- <sup>من</sup> Low/absent leukocyte alkaline phosphatase (LAP) scores

## □ Pathology

---



### Bone marrow:

- Markedly hypercellular owing to increased numbers of maturing **granulocytic and megakaryocytic precursors.**
- Mild reticulin fibrosis
- Blasts <10%


### Spleen

- Expanded red pulp with extramedullary hematopoiesis


CML—peripheral blood smear: Granulocytic forms at various stages of differentiation are present







⊗ hypercellular



## □ Course and Prognosis

---

- *Slow progression of 3 phases (chronic, accelerated, and blast crises phases).*

### Chronic phase

- 1-5 years
- Mild-moderate elevation of WBC
- Mild anemia
- Blasts <5% in BM
- Organomegaly, which responds to intermittent myelosuppression



## Accelerated phase

وضع المريض رح يصير أسوء

- 50% of CML cases
- Increase WBC count despite treatment
- Increasing anemia
- New thrombocytopenia
- The appearance of additional cytogenetic abnormalities ال cancer cells ما بتوقف عند حد معين
- Increasing splenic size despite treatment
- 10 - 19% blasts in BM acute leukemia اقل من 20% لهيك بعدنا ما وصلنا لل

## Blast crisis تحولنا من acute ل chronic

- $\geq 20\%$  blasts (definition of acute leukemia) or extramedullary blast proliferation
- Abrupt or gradual over weeks (**Can occur abruptly without the previous accelerating phase**)
- **70% are myeloid leukemia**
- **30% are lymphoid leukemia**
- Associated with additional chromosomal abnormalities

لي في احتمال يكون lymphoid ???  
لانه ال mutations الأساسية صارت في stem cells

NR

# Polycythemia

increase in the concentration of red blood cells in the bloodstream due to a decrease in plasma volume, rather than an actual increase in the production of red blood cells by the bone marrow.

## Causes of Polycythemia

• **Relative** : Reduced plasma volume(dehydration due vomiting or diarrhea): Hemoconcentration

• **Absolute**:

☐ **Primary**: PV

☐ **Secondary**: Increased Erythropoietin level:

- Adaptive: Lung disease, Smoking, cyanotic heart disease, high altitude living
- Paraneoplastic: Erythropoietin secreting tumors: RCC, HCC

## 2. Polycythemia Vera (PV)

إنزيم JAK2 بشتغل في ال pathway لل erythropoietin و ال thrombopoietin و ال mutation في هذا الإنزيم بزيد من ال proliferation في هاي الخلايا

- Insidious clonal disorder of pluripotential hematopoietic stem cells dominated by an expansion of the red cell mass.
- Strongly associated with activating mutations in the tyrosine kinase JAK2.
- This produces an excessive proliferation of erythroid, granulocytic, and megakaryocytic elements (**panmyelosis**). Poly = pan
- But most clinical signs and symptoms are related to an absolute **increase in red cell mass**.

### Ⓐ Associated with low levels of serum erythropoietin

If serum erythropoietin levels were high in a patient with polycythemia, it would be secondary polycythemia

كل الخلايا بيزيدوا لكن اكثر نوع هو ال erythroid cells فالبتالي زيادة في ال red mass لهيك اكثر الاعراض بتكون مرتبطة بال red mass

Major Criteria

لو ما عنا القدرة نعمل genetic testing ???

↑ Red mass يكون عنا زيادة بال

+

↓ Erythropoietin

+ panmyelosis in BM

Minor Criteria

Criteria required for diagnosis

2016 WHO Classification

1. **Hb > 16.5 g/dL in men/Hb > 16.0 g/dL in women, or Hct > 49% in men/Hct > 48% in women, or increased RCM;**
2. **BM biopsy showing hypercellularity** for age with trilineage growth (**panmyelosis**) including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature, megakaryocytes (differences in size);
3. **Presence of JAK2V617F or JAK2 exon 12 mutation** <sup>•/100</sup>

} → ↑ Red mass

Subnormal serum EPO level

All 3 major or the first 2 major and the minor criterion

## ❖ Clinical Findings

- Appears insidiously, in late middle age.

- Manifestations are related to expanded blood volume, increased blood viscosity, and thrombotic and hemorrhagic tendencies (Due to excessive distention of blood vessels and abnormal platelet function):

❖ Patients are plethoric and somewhat cyanotic.


*↑ RBCs*  
*plethoric: skin appears reddened due to increased blood volume or flow*

❖ Thrombosis and infarction: Especially heart, spleen, and liver (Hepatic vein thrombosis called Budd-Chiari syndrome).

❖ Headache, weakness, hypertension, GIT Sx, hematemesis, and melena are common

❖ Pruritus.

❖ Splenomegaly





## ❖ Laboratory Findings

كله عالي بس نتذكر هاي الخلايا شكلاً mature  
بس هي functionally abnormalities

---

- High red cell counts.

- High hematocrit

- High granulocyte count

- High platelet count (The platelets are functionally abnormal in most cases, and giant platelets and megakaryocyte fragments are often seen in the blood)

- Basophilia is common.

## ❖ Pathology

Bone marrow:

- Hypercellular owing to increased numbers of erythroid, myeloid, and megakaryocytic forms.

- Some degree of marrow fibrosis.

- Splenomegaly and enlarged liver

- Organs thromboses and infarctions

Chronic Myeloid Leukemia مهم نتذكر اي واحد من أنواع ال

acute leukaemia ممكن المريض يدخل في مرحلة ال

spent phase او ال

## ❖ PV Course & Prognosis

### - Proliferative phase

Erythroid proliferation

نستمر بسحب الدم من المريض

Median survival –10 years (With repeated phlebotomy)

- Spent phase: 15-20% (marrow fibrosis) كأنه ال bone marrow استهلاك صار

كله ألياف

- AML: 5-10%

ال survival يعتمد على ال treatment

- Without treatment, death occurs from vascular complications within months.

- With treatment, the median survival is increased.

